Gilead’s IBD drug eliminated symptoms for patients, mid-stage study finds

Gilead's emvistegrast eliminates symptoms in ulcerative colitis Phase 2 trial

Gilead Sciences reported mid-stage study results showing its oral α4β7 inhibitor emvistegrast eliminated symptoms in patients with ulcerative colitis, with remission rates exceeding those of Entyvio. The company plans to begin late-stage trials in 2027.